HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Public ClinicalTrials.gov record NCT03911388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Study identification
- NCT ID
- NCT03911388
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 24 participants
Conditions and interventions
Conditions
- Neoplasms, Brain
- Glioblastoma Multiforme
- Glioblastoma of Cerebellum
- Neoplasms
- Astrocytoma
- Astrocytoma, Cerebellar
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Cerebellar PNET, Childhood
- Cerebellar Neoplasms
- Cerebellar Neoplasms, Primary
- Cerebellar Neoplasm, Malignant
- Cerebellar Neoplasm Malignant Primary
- Neoplasm Metastases
- Neoplasm Malignant
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms, Primary
- Central Nervous System Neoplasms, Malignant
- Nervous System Neoplasms
- Neoplasms by Site
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Medulloblastoma Recurrent
- HSV
- Virus
- Pediatric Brain Tumor
- Nervous System Cancer
- Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Eligibility (public fields only)
- Age range
- 36 Months to 22 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 11, 2019
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2027
- Last update posted
- Sep 3, 2026
2019 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Cancer Center | Birmingham | Alabama | 35233 | Recruiting |
| Siteman Cancer Center at Washington University | St Louis | Missouri | 63110 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03911388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03911388 live on ClinicalTrials.gov.